Flush with $165M IPO cash, Zen­tal­is en­tices Ty­bourne, Or­biMed to fund a $20M Chi­na joint ven­ture

Weeks af­ter jump­ing in­to the pub­lic eye with an up­sized $165 mil­lion IPO ($190 mil­lion if you count the over­al­lot­ment), set­ting an up­beat tone for the lat­er pan­dem­ic biotech floats, Zen­tal­is Phar­ma­ceu­ti­cals is fol­low­ing up with a plan to take three of its ex­per­i­men­tal can­cer drugs to Chi­na.

Ty­bourne Cap­i­tal Man­age­ment had led a $20 mil­lion Se­ries A for Zen­tera Ther­a­peu­tics, a joint ven­ture tasked with de­vel­op­ing and com­mer­cial­iz­ing cur­rent and fu­ture drugs out of Zen­tal­is. Or­biMed Asia al­so came on board, though Zen­tal­is re­mains the ma­jor­i­ty share­hold­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER